|Bid||5.23 x 3100|
|Ask||5.55 x 1200|
|Day's Range||5.25 - 5.49|
|52 Week Range||3.39 - 9.00|
|Beta (5Y Monthly)||1.30|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 03, 2021 - May 07, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.72|
SAN DIEGO and TORONTO, April 08, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate in Canaccord Genuity’s 2021 Horizons in Oncology Virtual Conference: Canaccord Genuity’s 2021 Horizons in Oncology Virtual Conference Panel: Opportunities in BPDCN and AML Date:Thursday, April 15, 2021 Time:3:00 – 3:55 PM EDT Format:Panel Moderated by John Newman, Ph.D., Managing Director, Biotechnology Analyst Conference Information: Link The Aptose management team also will be hosting 1x1 meetings during the event. About Aptose Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products for hematologic malignancies: luxeptinib (CG-806), an oral, first-in-class mutation-agnostic FLT3/BTK kinase inhibitor, is in a Phase 1a/b trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), who have failed or are intolerant to standard therapies, and is in a separate Phase 1a/b trial in patients with relapsed or refractory acute myeloid leukemia (AML); APTO-253, the only clinical-stage agent that directly targets the MYC oncogene and suppresses its expression, is in a Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS). For further information, please contact: Aptose Biosciences Inc. Susan Pietropaolo Investor Relations firstname.lastname@example.org LifeSci Advisors, LLC Dan Ferry, Managing Director 617-535-7746 Daniel@LifeSciAdvisors.com
The huge gain came after the company provided a fourth-quarter update following the market close on Tuesday that featured new results from an early-stage clinical study evaluating luxeptinib in treating acute myeloid leukemia (AML). Aptose announced "encouraging anti-leukemic activity" has been observed so far in its phase 1 study of luxeptinib in treating AML. One patient in the study has experienced a complete remission with no safety issues.
Aptose Biosciences Inc (NASDAQ: APTO) shares are trading higher after the company reported fourth-quarter earnings results. Oppenheimer analyst Matthew Biegler also maintains Aptose with an Outperform and raises the price target from $8 to $9. Aptose is a biotechnology company. The company develops targeted medicines and personalized therapies for the precision treatment of life-threatening cancers such as acute myeloid leukemia, myelodysplastic syndromes and other hematologic malignancies and also therapies for Oncology. SenesTech Inc (NASDAQ: SNES) shares are trading higher after the company announced the initiation of a collaboration with Liphatech to develop a non-liquid formulation of ContraPest. SenesTech is a biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company provides its solutions to the animal market, commercial markets, and food markets. See also: Best Penny Stocks Under See more from BenzingaClick here for options trades from BenzingaWhat's Happening With LIVX Stock And EYES Stock Wednesday?Thinking About Buying Stock Or Options In Wells Fargo, Netflix, Microsoft Or Apple?© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.